LRMR · Larimar Therapeutics, Inc.

Larimar Therapeutics announced its first quarter 2026 financial results alongside significant clinical and regulatory progress for nomlabofusp, its lead candidate for Friedreich’s ataxia (FA). The company reported a GAAP net loss of $29.6 million, or $0.31 per share, on 89.8 million weighted average common shares, compared to $29.3 million, or $0.46 per share, in the prior year quarter on fewer shares. R&D expenses decreased to $25.0 million from $26.6 million, driven by lower nomlabofusp manufacturing costs ($3.1M reduction) and clinical trial costs ($0.5M), offset by higher BLA preparation consulting fees ($1.6M). G&A expenses rose to $6.1 million from $4.6 million due to commercial consulting and headcount increases. Balance sheet strengthened significantly with $200.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, following a $107.6 million net proceeds public offering in February, extending runway into Q2 2027. CEO Carole Ben-Maimon highlighted momentum toward BLA submission, with plans for accelerated approval via rolling submission starting June 2026 (nonclinical/clinical modules), followed by CMC in H2 2026. Key supports include FDA alignment on skin FXN as surrogate endpoint, Breakthrough Therapy Designation, and upcoming Q2 topline open-label data plus Phase 3 initiation mid-2026. A recent peer-reviewed publication reinforced cross-species FXN correlations across tissues, bolstering the surrogate endpoint rationale. These milestones position nomlabofusp as potential first disease-modifying FA therapy, with Type B FDA meeting scheduled Q2 2026.